Bnp and Ntprobnp Market to Reach $3.4 Billion, Globally, by 2031 | 12.2% CAGR

The global Bnp and Ntprobnp industry generated $1.1 billion in 2021, and is anticipated to generate $3.4 billion by 2031, witnessing a CAGR of 12.2% from 2022 to 2031.

𝐏𝐫𝐢𝐦𝐞 𝐝𝐞𝐭𝐞𝐫𝐦𝐢𝐧𝐚𝐧𝐭𝐬 𝐨𝐟 𝐠𝐫𝐨𝐰𝐭𝐡

The high potential in emerging markets, such as India and Japan, due to the availability of improved healthcare infrastructure, increase in unmet healthcare needs, rise in the prevalence of heart-related diseases, and rise in awareness about BNP and NTproBNP biomarkers testing drives the growth of the global bnp and ntprobnp market. However, the stringent government regulations regarding biomarkers testing restrict the market growth. Moreover, growth & innovations in the medical devices industry for the manufacturing of advanced diagnostic and biomarker testing, owing to a massive pool of health-conscious consumers, presents new opportunities in the coming years.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭@ https://www.alliedmarketresearch.com/request-sample/53979

𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐂𝐨𝐯𝐢𝐝-𝟏𝟗 𝐨𝐧 𝐁𝐧𝐩 𝐚𝐧𝐝 𝐍𝐭𝐩𝐫𝐨𝐛𝐧𝐩 𝐌𝐚𝐫𝐤𝐞𝐭:

The outbreak of the Covid-19 pandemic had a negative impact on the global bnp and ntprobnp market, owing to severe disruptions in workflows of the healthcare sector around the world during the lockdown.

The global BNP and NTproBNP market share experienced a decline in 2020, due to the global economic recession led by COVID-19.

In addition, the COVID-19 outbreak disrupted the supply chain and delayed diagnostic testing using BNP and NTproBNP biomarkers.

However, COVID-19 was itself potentially associated with myocardial injury, arrhythmia, and venous and arterial thrombosis. It was therefore essential to optimize the diagnosis and management of cardiac disease, which eventually increased the use of point-of-care BNP and NT-proBNP testing.

𝐏𝐫𝐨𝐜𝐮𝐫𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 (𝟐𝟏𝟑 𝐏𝐚𝐠𝐞𝐬 𝐏𝐃𝐅 𝐰𝐢𝐭𝐡 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐂𝐡𝐚𝐫𝐭𝐬, 𝐓𝐚𝐛𝐥𝐞𝐬, 𝐚𝐧𝐝 𝐅𝐢𝐠𝐮𝐫𝐞𝐬) https://www.alliedmarketresearch.com/checkout-final/bnp-and-ntprobnp-market

𝐓𝐡𝐞 𝐦𝐲𝐨𝐜𝐚𝐫𝐝𝐢𝐚𝐥 𝐢𝐧𝐟𝐚𝐫𝐜𝐭𝐢𝐨𝐧 𝐬𝐞𝐠𝐦𝐞𝐧𝐭 𝐭𝐨 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧 𝐢𝐭𝐬 𝐥𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩 𝐬𝐭𝐚𝐭𝐮𝐬 𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐨𝐮𝐭 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝

Based on application, the myocardial infarction segment held the highest market share in 2021, accounting for more than one-third of the global bnp and ntprobnp market, and is estimated to maintain its leadership status throughout the forecast period. This segment is projected to manifest the highest CAGR of 12.8% from 2022 to 2031. This is due to rise in the number of cases of myocardial infarction, and the adoption of early diagnosis for prompt treatment which can help prevent further damage to the heart and increase the chances of survival.

𝐓𝐡𝐞 𝐩𝐨𝐢𝐧𝐭-𝐨𝐟-𝐜𝐚𝐫𝐞 𝐭𝐞𝐬𝐭𝐢𝐧𝐠 𝐬𝐞𝐠𝐦𝐞𝐧𝐭 𝐭𝐨 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧 𝐢𝐭𝐬 𝐥𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩 𝐬𝐭𝐚𝐭𝐮𝐬 𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐨𝐮𝐭 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝

Based on location of testing, the point-of-care testing segment held the highest market share in 2021, accounting for nearly three-fifths of the global bnp and ntprobnp market, and is estimated to maintain its leadership status throughout the forecast period. This segment is projected to manifest the highest CAGR of 12.4% from 2022 to 2031. This is attributed to improved diagnosis and treatment of heart failure, increased patient convenience, better resource utilization, improved clinical decision-making, and growth in demand for cardiac biomarker testing through point-of-care testing.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐄𝐧𝐪𝐮𝐢𝐫𝐲 𝐚𝐭: https://www.alliedmarketresearch.com/purchase-enquiry/53979

𝐀𝐬𝐢𝐚-𝐏𝐚𝐜𝐢𝐟𝐢𝐜 𝐭𝐨 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧 𝐢𝐭𝐬 𝐝𝐨𝐦𝐢𝐧𝐚𝐧𝐜𝐞 𝐛𝐲 𝟐𝟎𝟑𝟏

Based on region, Asia-Pacific held the highest market share in terms of revenue in 2021, accounting for more than one-third of the global bnp and ntprobnp market, and is likely to dominate the market during the forecast period. This region is expected to witness the fastest CAGR of 13.5% from 2022 to 2031. This is owing to the strong presence of several major players, such as Abbott PerkinElmer Inc., and Siemens AG, and technological advancement in diagnostic methods in the region.

𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:

Scripps Laboratories
Abbott Laboratories
Danaher Corporation
Gentian Diagnostics ASA
Siemens AG
PerkinElmer Inc.
Biomerieux SA
Quidel Corporation
Bio-Rad Laboratories Inc.
F Hoffman La Roche Ltd.

𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲:

Gene Synthesis Market Size: https://www.alliedmarketresearch.com/gene-synthesis-market-A39015

Mobile Tomography Market Share: https://www.alliedmarketresearch.com/mobile-tomography-market-A31901

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

David Correa

5933 NE Win Sivers Drive

205, Portland, OR 97220

United States

USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1(855)550-5975

help@alliedmarketresearch.com

𝐀𝐛𝐨𝐮𝐭 𝐮𝐬:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.